Where Will Applied Therapeutics Inc (APLT) Stock Go Next After It Has Gained 57.50% in a Week?

Overall market sentiment has been high on Applied Therapeutics Inc (APLT) stock lately. APLT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Applied Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on APLT!

See Full APLT Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With APLT Stock Today?

Applied Therapeutics Inc (APLT) stock has gained 27.27% while the S&P 500 is lower by -0.37% as of 3:13 PM on Tuesday, Sep 19. APLT is up $0.54 from the previous closing price of $1.98 on volume of 2,672,318 shares. Over the past year the S&P 500 has risen 13.77% while APLT is up 115.38%. APLT lost -$1.24 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Applied Therapeutics Inc click here.

More About Applied Therapeutics Inc

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Click Here to get the full Stock Report for Applied Therapeutics Inc stock.